Search Results for:

Global Biosimilar Market Update: Secukinumab Biosimilar Approval in China and Expanded Ustekinumab Licensing Rights

On October 26, 2026, Bio-Thera Solutions announced that China’s National Medical Products Administration (“NMPA”) approved BAT2306, its biosimilar to COSENTYX® (secukinumab). BAT2306 will be marketed as YOUZHUOMEI® and is approved for psoriasis, ankylosing spondylitis, and psoriatic arthritis. According to Bio-Thera, BAT2306 is the first secukinumab biosimilar approved in China. Bio-Thera…

Read More

FDA Approves Lupin’s Ranibizumab Biosimilar

On June 5, Lupin announced that the U.S. Food and Drug Administration (“FDA”) approved RANLUSPEC, a ranibizumab biosimilar to Genentech’s LUCENTIS®. RANLUSPEC, which received European Marketing Authorization earlier this year, is indicated for the treatment of neovascular (wet) age-related macular degeneration and other retinal vascular disorders. It is the only…

Read More